Resource Summary Report

Generated by NIF on Sep 9, 2026

OV-90

RRID:CVCL_3768
Type: Cell Line

Proper Citation

RRID:CVCL_3768

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3768

Proper Citation: RRID:CVCL_3768

Description: Cell line OV-90 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian adenocarcinoma

Defining Citation: PMID:10949993, PMID:11641787, PMID:20204287, PMID:20215515, PMID:22141344, PMID:22328975, PMID:22460905, PMID:22585861, PMID:22710073, PMID:23839242, PMID:24023729, PMID:24675677, PMID:25230021, PMID:25485619, PMID:25877200, PMID:25984343, PMID:26589293, PMID:27235858, PMID:27397505, PMID:28196595, PMID:28273451, PMID:30485824, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OV-90

Synonyms: OV90

Cross References: BTO:BTO_0004852, CLO:CLO_0008276, EFO:EFO_0002311, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-3585, ATCC:CRL-11732,

BioGRID_ORCS_Cell_line:393, BioSample:SAMN03471308, BioSample:SAMN10987765, cancercelllines:CVCL_3768, CancerTools:161765, Cell_Model_Passport:SIDM01141, ChEMBL-Cells:CHEMBL4295466, ChEMBL-Targets:CHEMBL4296481, CLS:305849, Cosmic:1102815, Cosmic:1113283, Cosmic:1139219, Cosmic:1305311, Cosmic:1709257, Cosmic:2186586, Cosmic-CLP:1240197, DepMap:ACH-000291, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240197, GEO:GSM274704, GEO:GSM659389, GEO:GSM711702, GEO:GSM784576, GEO:GSM851926, GEO:GSM887483, GEO:GSM888564, GEO:GSM1001427, GEO:GSM1001428, GEO:GSM1001492, GEO:GSM1291148, GEO:GSM1374800, GEO:GSM1670314, GEO:GSM2474988, IARC_TP53:20198, IGRhCellID:OV90, LiGeA:CCLE_009, LINCS_LDP:LCL-1523, PharmacoDB:OV90_1210_2019, PRIDE:PXD030304, Progenetix:CVCL_3768, PubChem_Cell_line:CVCL_3768, Wikidata:Q54936833

ID: CVCL_3768

Record Creation Time: 20220427T221402+0000

Record Last Update: 20260905T182005+0000

Ratings and Alerts

No rating or validation information has been found for OV-90.

No alerts have been found for OV-90.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Gjerde CH, et al. (2026) A 3D ovarian cancer metastasis model using a decellularised peritoneal matrix to study therapy response. EBioMedicine, 124, 106135.

Gendrau-Sanclemente N, et al. (2026) Sphingosine-1-Phosphate Receptor 1 Promotes Ovarian Cancer Tumorsphere Proliferation and Metastasis. International journal of cancer, 159(3), 768.

Lujano-Olazaba O, et al. (2026) RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer. Cell reports, 45(7), 117650.

Uno K, et al. (2026) Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation. Science advances, 12(6), eadu5944.

Guo X, et al. (2026) The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. iScience, 29(7), 116390.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell, 189(10), 2898.

Wang Z, et al. (2026) PTEN loss drives B7H3 upregulation via the mTORC2/FOXO/c-Myc axis to promote tumor immune escape in ovarian cancer. Cell reports, 45(4), 117198.

Kimura N, et al. (2026) CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. Cancer research communications, 6(2), 383.

Elhaw AT, et al. (2026) RHOV Is a Detachment-Responsive Rho GTPase Necessary for Ovarian Cancer Peritoneal Metastasis. Cancer research, 86(11), 2623.

Criscuolo D, et al. (2026) CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC. Cancer research communications, 6(1), 201.

Zoeller JJ, et al. (2025) Derivation of AZD5335, a Novel FR??-Targeted TOP1i-Loaded ADC, for the Treatment of FR??-Expressing Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(24), 5261.

Hu Y, et al. (2025) Targeting PRDX6-dependent localization and function of GPX4 enhances ferroptosis-mediated tumor suppression. Molecular cell, 85(24), 4602.

Foote JB, et al. (2025) A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer. Cancer research, 85(5), 956.

Davies LT, et al. (2025) Plasma-activated media selectively induces apoptotic death via an orchestrated oxidative stress pathway in high-grade serous ovarian cancer cells. Molecular oncology, 19(4), 1170.

Kavaklioglu G, et al. (2025) The domesticated transposon protein L1TD1 associates with its ancestor L1 ORF1p to promote LINE-1 retrotransposition. eLife, 13.

Cheng YY, et al. (2025) Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer. Cancer research communications, 5(7), 1180.

Abrantes R, et al. (2025) Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors. Cell reports. Medicine, 6(9), 102350.

Kim D, et al. (2025) Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. NPJ precision oncology, 9(1), 3.

Jones T, et al. (2025) TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network. Science advances, 11(9), eadr9660.

Chandra V, et al. (2025) Mortalin and PINK1/Parkin-Mediated Mitophagy Represent Ovarian Cancer-Selective Targets for Drug Development. Advanced science (Weinheim,

Baden-Wurttemberg, Germany), e05592.